HELIX DIAGNOSTICS
Pharmacogenomics (PGx) Clopidogrel Test
Test Description
Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.
This test evaluates a patient’s metabolizer status for CYP2C19, which can aid in appropriate prescription and dosing to reduce risk of side effects and treatment failure with clopidogrel.
Genes Tested (1)
Important Test Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
In order to successfully prevent platelet collection and clot formation, clopidogrel is turned into its active metabolite by CYP2C19. An individual’s CYP2C19 genotype can impact the concentration of active metabolite in the plasma, which may increase risk for treatment failure and adverse cardiac and cerebrovascular events such as heart attack and stroke. Knowing a patient’s CYP2C19 genotype can help determine whether there should be a change in medication to reduce this risk.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.